| Ms Heather Alethea Rhodes-hughes, LPE-I | |
|
4505 Tanya Cir, Russellville, AR 72802-8559 | |
| (479) 886-2652 | |
| (479) 498-4904 |
| Full Name | Ms Heather Alethea Rhodes-hughes |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 4505 Tanya Cir, Russellville, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851685945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 13-04EI (Arkansas) | Secondary |
| 101YM0800X | Counselor - Mental Health | 13-04EI (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Heather Alethea Rhodes-hughes, LPE-I 4505 Tanya Cir, Russellville, AR 72802-8559 Ph: (479) 886-2652 | Ms Heather Alethea Rhodes-hughes, LPE-I 4505 Tanya Cir, Russellville, AR 72802-8559 Ph: (479) 886-2652 |
News Archive
A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.
Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.
Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.
"Overall, we found that patients who elect to have duodenal switch end up slimmer than those who choose gastric bypass," says Dr. Gladys W. Strain, director of research for bariatric surgery at NewYork-Presbyterian/Weill Cornell and associate research professor of nutrition in surgery at Weill Medical College of Cornell University.
Stroke survivors may be more likely to attempt or die by suicide than people who have not had a stroke, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 7 days ago